Tirzepatide

What is Tirzepatide?

Tirzepatide (LY3298176) is a synthetic peptide developed to simultaneously target GIP and GLP-1 receptors. These incretin hormones regulate blood glucose and energy balance. By mimicking both, Tirzepatide offers a dual mechanism of action that has shown enhanced efficacy in clinical studies. Research indicates that it can significantly reduce hemoglobin A1c and body weight, positioning it as a promising agent for metabolic disorder research [1].

Structure

• Chemical Formula: C₂₂₅H₃₄₀N₄₈O₆₈
• Synonyms: LY3298176

(Note: Detailed amino acid sequence is not publicly disclosed.)

Tirzepatide Research

Tirzepatide in Type 2 Diabetes Management

The SURPASS-2 clinical trial found that Tirzepatide produced greater reductions in HbA1c levels than semaglutide in patients with type 2 diabetes. Participants experienced improved insulin sensitivity and fasting glucose levels, suggesting Tirzepatide’s dual action could offer more comprehensive glycemic control than single-receptor therapies [1].

Tirzepatide and Weight Management

In the SURMOUNT-1 trial, Tirzepatide led to significant weight reduction in people with obesity, independent of diabetes status. Participants lost up to 22.5% of body weight over 72 weeks. This robust effect is believed to result from enhanced satiety and delayed gastric emptying mediated by both GLP-1 and GIP receptor activation [2].

Cardiovascular Benefits of Tirzepatide

Beyond metabolic improvements, Tirzepatide has demonstrated potential cardiovascular benefits. Early results from long-term outcome studies suggest reductions in blood pressure, lipid levels, and major adverse cardiovascular events (MACE), though more research is needed to confirm these findings [1].

Tirzepatide and Non-Alcoholic Steatohepatitis (NASH)

Emerging preclinical and clinical research indicates Tirzepatide may reduce liver fat and improve inflammation in metabolic dysfunction-associated steatohepatitis (MASH/NASH). These effects are thought to be mediated by weight loss, insulin sensitivity improvement, and anti-inflammatory signaling [1].

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Referenced Citations

1. Tirzepatide. Wikipedia. Accessed April 1, 2025. Available at: https://en.wikipedia.org/wiki/Tirzepatide 

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” The New England Journal of Medicine. 2022;387(3):205–216. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038